Avastin Alarm

Adjuvant osimertinib reduced the risk of death by 51% compared with placebo for patients with EGFR-mutated, stage IB, II, or IIIA non–small cell lung cancer.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Prospective phase 2 data demonstrated that aumolertinib, followed by salvage stereotactic radiation therapy, elicited responses in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.

Single-agent adagrasib demonstrated a manageable safety profile and meaningful clinical activity in patients with KRAS G12C–mutated solid tumors.

The addition of toripalimab to perioperative chemotherapy led to a statistically significant improvement in event-free survival for patients with non–small cell lung cancer.